|
|
| Monday, June 4, 2012
|
|
4:00 PM - 5:00 PM
|
|
The 16th Annual Andrew H. Weinberg Symposium--Whole Genome Sequencing of Pediatric Cancers
|
| Description: |
James R. Downing, MD Deputy Director, St. Jude Children's Research Hospital, Scientific Director and Executive Vice President, St. Jude Children's Research Hospital, Associate Director of Basic Research, Cancer Center.
Place: Children's Hospital Boston, 300 Longwood Avenue, Enders Research Building, Byers Conference Rooms A and B
In January 2010, St. Jude Children's Research Hospital and Washington University School of Medicine in St. Louis announced an unprecedented effort to identify the genetic changes that give rise to some of the world's deadliest childhood cancers. The team joined forces to decode the genomes of more than 600 childhood cancer patients. The St. Jude Children's Research Hospital – Washington University Pediatric Cancer Genome Project is the largest investment to date aimed at understanding the genetic origins of childhood cancers. Scientists involved in the project are sequencing the entire genomes of both normal and cancer cells from each patient, comparing differences in the DNA to identify genetic mistakes that lead to cancer.
The mission of the Andrew H. Weinberg Annual Memorial Fund is to bring together researchers from the field of chemotherapy development and the medical community in an annual symposium to create and foster an environment for cooperative synergy for inspiring and developing new concepts in pediatric cancer research and treatment.
|
| Contact: |
Sarah Hagan
|
|
| Tuesday, June 5, 2012
|
|
4:00 PM - 5:00 PM
|
|
| Wednesday, June 6, 2012
|
|
9:00 AM - 5:00 PM
|
|
BU Bioinformatics Graduate Program Student Run Symposium
|
| Description: |
SPEAKERS:
Atul J. Butte, Stanford
David Stern, Janelia Farm Research
Sarah Teichmann, Medical Research Council Laboratory of Molecular Biology
King Jordan, Georgia Institute of Technology
Martin Frith, Computational Biology Research Center (CBRC) in Japan
For more information visit http://www.bu.edu/bioinformatics/news/annual-student-organized-symposium/
|
| Contact: |
Johanna Vasquez
|
|
| Thursday, June 7, 2012
|
|
Noon - 1:00 PM
|
|
The effect of targeting activin receptor type IIB signaling on the regulation of muscle, bone and fat
|
| Description: |
Speaker: Jennifer L. Lachey, PhD, Associate Director, Preclinical Pharmacology Acceleron Pharma
Location: The Forsyth Institute, Seminar Room A, 245 First Street, 17th Floor, Cambridge
Summary : The activin receptor type IIB (ActRIIB) is a signaling receptor for multiple TGF superfamily ligands including activins A and B and myostatin. These ligands have been implicated in the development and homeostasis of a variety of different tissue types. For example, myostatin has been characterized as a potent inhibitor of muscle development which also regulates adipose and bone mass. Previous studies in normal animals demonstrated that inhibition of ActRIIB signaling promotes muscle and bone mass gain while decreasing fat mass. ACE-031 is an ActRIIB-IgG fusion protein that acts as a soluble decoy receptor and binds myostatin and other high-affinity ActRIIB ligands, blocking their signaling through endogenous receptors. Results from non-clinical studies and two phase 1 clinical studies demonstrate that ACE-031 is generally well-tolerated and has rapid and sustained effects on muscle, fat and bone. These results support further studies of ACE-031 in neuromuscular diseases to improve muscle mass, strength, and function.
|
| Contact: |
Pam Quattrocchi
|
|
 |
|
|
Week of Sunday, June 3, 2012
